secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001493152-26-020586
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma presents CDI-988 data at ICAR 2026; Phase 1b norovirus study fully enrolled in stage 1
--------------------------------------------------------------------------------

- CDI-988 mechanism and Phase 1b human challenge study featured at ICAR 2026 in Prague.
- Phase 1b study fully enrolled first cohort to assess infectivity of GII.2 Snow Mountain Virus inoculum.
- CDI-988 is first oral direct-acting antiviral for norovirus; targets conserved 3CL protease across strains.
- FDA Fast Track designation granted for CDI-988 for norovirus treatment and prophylaxis.
- No approved treatments or vaccines for norovirus; $60 billion annual economic burden.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226020586/0001493152-26-020586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315226020586/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-020586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer